MET and kidney cancer: In the present study, we found that MET expression was high in various histological types of BHD-associated kidney cancer, raising the possibility that MET inhibitors, such as cabozantinib and crizotinib, may provide promising therapeutic approaches for treatment of BHD-associated kidney cancer.